🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Medexus Pharmaceuticals Inc. (TSX:MDP)
Canada flag Canada · Delayed Price · Currency is CAD
5.71
-0.26 (-4.36%)
Nov 19, 2026, 4:00 PM EST
← View all transcripts

Earnings Call: Q2 2027

Nov 12, 2026

Summary

Q2 revenue rose to $29.1M and Adjusted EBITDA to $5.1M, with net income of $0.8M. GRAFAPEX adoption is expanding, and FY27 product-level revenue guidance remains $30M–$32M.

Operator

Good day, everyone, and welcome to Medexus Pharmaceuticals' second quarter 2027 conference call. At this time, all participants are placed on a listen-only mode. If you have any questions or comments during the presentation, you may press star one on your phone to enter the question queue at any time, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to hand the floor over to your host, Victoria Rutherford. Ma'am, the floor is yours.

Victoria Rutherford
Investor Relations Representative, Adelaide Capital

Thank you, and good morning, everyone. Welcome to the Medexus Pharmaceuticals second fiscal quarter 2027 earnings call. On the call this morning are Ken d'Entremont, Chief Executive Officer, and Brendon Buschman, Chief Financial Officer. If you have any questions after the conference or would like further information about the company, please contact Adelaide Capital at 480-625-5772.

I would like to remind everyone that this discussion will include forward-looking information as defined in Canadian securities laws that is based on certain assumptions that Medexus believes to be reasonable in the circumstances, but is subject to risks and uncertainties. Actual results may differ materially from historical results or results anticipated by the forward-looking information.

In addition, this discussion will also include non-GAAP measures such as Adjusted EBITDA, adjusted gross margin, net debt, and related measures, which do not have any standardized meaning under IFRS, and therefore may not be comparable to similar measures presented by other companies.

For more information about forward-looking information and non-GAAP measures, including reconciliations, please refer to the company's MD&A, which, along with the financial statements, is available on the company's website at www.medexus.com and on SEDAR+ at www.sedarplus.ca.

As a reminder, Medexus reports on a March 31st fiscal year basis. Medexus reports financial results in USD, and all references are to USD unless otherwise specified. I would now like to turn the call over to Ken d'Entremont.

Ken d'Entremont
CEO, Medexus Pharmaceuticals

Thank you, Victoria, and good morning, everyone. We are pleased with our second quarter performance and the continued strength of our business, supported by solid Adjusted EBITDA, healthy operating cash flow, and the company's strong financial position. A key contributor to this quarter's performance was our continued progress in the commercialization of GRAFAPEX, and we remain encouraged by the significant growth opportunity ahead.

During fiscal Q2 2027, GRAFAPEX generated $5.7 million in product-level net revenue compared to approximately $3.8 million in related personnel and infrastructure investments, plus $0.7 million in cost of product and amortization in the same period, reflecting continued progress in scaling the product. With a dedicated sales team deployed and early commercial indicators trending positively, we believe we are well-positioned to accelerate awareness and adoption.

This progress, in particular our expanded commercial capabilities, reinforces our confidence that product-level net revenue of GRAFAPEX for fiscal year 2027 will be between $30 million and $32 million. We are encouraged by the early indicators, and we have seen and believe our expanded commercial presence positions us well to maintain momentum throughout the remainder of the fiscal year.

Commercial adoption also continues to progress well. Wholesaler data as of September 30, 2026, shows that 86 individual healthcare institutions have already ordered GRAFAPEX for procedures in their institutions, and 38 of those institutions have placed multiple orders in the most recent completed six-month period.

Ordering by healthcare institutions and payer coverage and access trends have been highly encouraging, and the early indicators of patient-level demand continue to reinforce the value proposition GRAFAPEX brings to patients, providers, and payers.

Based on the continued commercial traction we are seeing, we continue to expect GRAFAPEX to achieve annual product-level net revenue of approximately $100 million-$175 million within five years after commercial launch. Turning to our overall financial results, net revenue for fiscal Q2 2027 increased to $29.1 million from $24.7 million in the prior year period, while Adjusted EBITDA increased to $5.1 million from $4.4 million.

We also generated net income of $0.8 million compared to a net loss of $0.3 million in the prior year period, and operating income improved to $2.4 million, up from $1.4 million. Beyond GRAFAPEX, our portfolio of established products continues to provide a solid foundation for the business, supported by sustained total underlying demand across key products.

This stability, together with our stable financial position, allows us to remain focused on our growth opportunities, most notably the continued commercialization of GRAFAPEX and the longer-term potential of UM171 cell therapy in Canada.

We believe these opportunities position Medexus well for its next phase of growth as we continue to execute on our strategic plan, generate operating cash flow, and invest in creating long-term value. I will now turn the call over to Brendon, who will discuss our financial results in more detail. Brendon?

Brendon Buschman
CFO, Medexus Pharmaceuticals

Thank you, Ken. Our second quarter results reflected the continued momentum of GRAFAPEX, the stability of our portfolio of established products, and the strength of our financial position, supported by growing revenues. Solid Adjusted EBITDA and healthy operating cash flows.

As Ken mentioned, we generated $5.7 million of product level net revenue from GRAFAPEX in fiscal Q2 2027, and we continue to expect increasing GRAFAPEX product level net revenue to have a positive effect on operating cash flow. Product level performance of GRAFAPEX continues to reflect meaningful growth.

Underlying patient demand was $5.6 million for fiscal Q2 2027, representing growth of 16% compared to $4.8 million for fiscal Q1 2027, and 156% compared to $2.1 million for fiscal Q2 2026. Turning to the full quarterly results, total net revenue for fiscal Q2 2027 was $29.1 million.

This represents an increase of $4.4 million compared to $24.7 million for the same period last year. The $4.4 million year-over-year net revenue increase was primarily due to an increase in product level net revenue from GRAFAPEX and IXINITY among other factors. Gross profit was $16.3 million for fiscal Q2 2027, compared to $13.8 million for the same period last year.

Gross margin was 55.9% for fiscal Q2 2027, compared to a gross margin of 55.7% for the same period last year. Adjusted gross margin was 64% compared to 65.2% for the same period last year.

Year-over-year changes in gross margin and adjusted gross margin are primarily due to the changes in the relative contribution of product level net revenue, in particular, an increasing level of net sales of GRAFAPEX and a higher cost of sales of products for IXINITY in fiscal year 2027.

Selling, general, and administrative expenses were $13.3 million for fiscal Q2 2027, compared to $11.9 million for the same period last year. Adjusted EBITDA was $5.1 million for fiscal Q2 2027, an increase of $0.7 million compared to $4.4 million for the same period last year.

The $0.7 million year-over-year Adjusted EBITDA increase was primarily due to the $5.7 million of product level net revenue from GRAFAPEX for fiscal Q2 2027, exceeding the $3.8 million of GRAFAPEX personnel and infrastructure investments, plus $0.7 million of cost of sales of products before amortization in the same period.

This improvement was partially offset by the impact of generic competition on Rupall. Net income was $0.8 million for fiscal Q2 2027, an increase of $1.1 million compared to a net loss of $0.3 million in Q2 2026.

Cash provided by operating activities was $5.4 million for fiscal Q2 2027, an increase of $2.1 million compared to $3.3 million of cash provided by operating activities for the same period last year. Part of this improvement is due to working capital and payment timing, although we continue to expect increasing GRAFAPEX product level net revenue to have a positive effect on operating cash flow over time.

As of September 30, 2026, our net debt was $17.9 million, an increase of $2.1 million compared to $15.7 million as at March 31, 2026. Net debt to Adjusted EBITDA was 0.97 times as of September 30, 2026. We remain in a strong position, supported by healthy operating cash flows and the continued contribution of our overall portfolio to company performance.

While quarterly results may vary, we believe the foundation we have built over the past quarters will provide us with the flexibility to support the continued commercialization of GRAFAPEX and pursue opportunities that drive long-term growth. Operator, we will now open the call to analyst questions.

Operator

Certainly. Everyone at this time will be conducting a question -and -answer session. If you have any questions or comments, please press star one on your phone at this time. We do ask that while posing your question, please pick up your handset if you're listening on speakerphone to provide optimum sound quality. Once again, if you have any questions or comments, please press star one on your phone. Your first question's coming from Scott Henry from Alliance Global. Your line is live.

Scott Henry
Analyst, Alliance Global

Thank you, and good morning. First, great execution. You've really strung together a lot of solid quarters in the GRAFAPEX launch. That brings me to my question. Obviously, GRAFAPEX is launching very well, but looking at the numbers, to get to 30- 32 is going to take a significant jump from what we saw in the first half of the year, not just continuation of trends.

What are you seeing that gives you confidence that we're not just continuing to have the good things happen, but they're actually going to accelerate? Just wanted to get a sense of that. Thank you.

Ken d'Entremont
CEO, Medexus Pharmaceuticals

Yeah. Thank you, Scott. Great question. I'm sure that's on a lot of people's minds. What we're seeing in field is very much what expected. Remember, when we launched this product, there was no experience in the U.S. with this drug. All the development had been done elsewhere, with the exception of one center, which was Fred Hutch.

So we clearly knew that we had to build belief within the whole market across the 170-some-odd institutions. We've been doing that, and doing that successfully. I think that's what's driven our revenues to this point. We've now gotten to a point where there is evidence that's being generated from the U.S. market that will be shared beginning at ASH, and then obviously through Tandem Meetings.

That is what gives us strong belief that we will see an acceleration in our revenues as real-world evidence from the U.S. market starts to be shared. We really think that's what will drive institutions that haven't yet adopted the drug to adopt it, and those who are already starting to use it to use more. We've got a high degree of confidence that the drug will continue to perform well. With our execution that has been solid to this point, we'll see that growth that we expect.

Scott Henry
Analyst, Alliance Global

Okay. And sort of a follow-up to that, do you expect most of that inflection in the fiscal third quarter, your December quarter, or next year's March quarter? Along those lines, we are already halfway through the December quarter. How are you feeling about when we should see that significant continued inflection?

Ken d'Entremont
CEO, Medexus Pharmaceuticals

Yeah, I think it will be spread over the two quarters. ASH is mid-early December this year. So, there will be significant evidence presented there, which will start to accelerate. Then through fourth quarter, I think we will see strong uptake. We are seeing progress now. With more and more institutions coming on board and sharing their experience with their colleagues, that clearly supports our launch.

Scott Henry
Analyst, Alliance Global

Okay, great. Thank you for that color. With regards to UM171, obviously you have the Canadian rights. I believe someone else just picked up the European rights. What are your thoughts on the timeline of what could happen with the U.S. rights, and is that likely going to indicate what happens for the future clinical pathway of the product?

Ken d'Entremont
CEO, Medexus Pharmaceuticals

Yeah, as evidenced by the fact that we licensed it for Canada, I think we are strong supporters of the product. We see a good potential for the product, but I cannot really comment on licensing discussions that might be ongoing.

Scott Henry
Analyst, Alliance Global

Okay, fair enough. One just clerical question. Did I see this right? Were Canadian sales $5,932,000 in both Q1 and Q2? I just didn't know if that was a typo.

Ken d'Entremont
CEO, Medexus Pharmaceuticals

Brendon?

Brendon Buschman
CFO, Medexus Pharmaceuticals

Yeah. No, that should be correct.

Scott Henry
Analyst, Alliance Global

Okay. It's unusual. All right, thank you for taking the question.

Operator

Thank you. Once again, everyone, if you have any questions or comments, please press star then one on your phone. Your next question's coming from Andre Uddin from Research Capital. Your line is live.

Andre Uddin
Analyst, Research Capital

Thanks, operator. Hi, Ken and Brendon. Nice quarter. Just need a little bit more clarity. Given that Zemcelpro received conditional marketing authorization from the European Commission, are you planning on using that dossier to follow your NDS in Canada, or will you wait for more data? When should we expect that filing to take place? Thanks.

Ken d'Entremont
CEO, Medexus Pharmaceuticals

Thanks, Andre. Yeah, I think the first step in Canada is getting clarity from Health Canada on what paths are available to us. We would certainly be interested in using the path that was forged by ExCellThera in Europe, being able to make the product available for those patients who simply don't have a donor. We don't yet know if that path is available to us in Canada. That's why I think when we licensed it, we gave kind of a range of launch dates, which was between 2028 and 2031, I believe.

Andre Uddin
Analyst, Research Capital

Okay, that's fair. That's fair. Just, if we're looking at the prescription trends for GRAFAPEX, they look strong. Should we expect similar seasonal sales patterns for GRAFAPEX next year?

Ken d'Entremont
CEO, Medexus Pharmaceuticals

Yeah, really good question. We've been trying to tease out seasonality on GRAFAPEX for a while. As we get more and more volume, it's getting a little bit easier. There's not a really well-defined seasonality for this space, other than I would say that when transplanters are not in the institution around holidays, like the upcoming Thanksgiving period in the U.S., and then the Christmas period also, we do see a decline in number of transplants done.

But no clear seasonality. I think non-malignant disease is a little bit different, which is primarily children, where they would try to avoid the summer period. So, yeah, there's a little bit of seasonality, but it's not overwhelming.

Andre Uddin
Analyst, Research Capital

Okay. Okay, thanks. That is it for me.

Operator

Thank you. That concludes our Q&A session. I will now hand the conference back to Ken d'Entremont for closing remarks. Please go ahead.

Ken d'Entremont
CEO, Medexus Pharmaceuticals

Well, I would like to thank you all for your participation. We are pleased with our performance through the first half of fiscal 2027 and remain confident in the strength of our business and the opportunities ahead.

With continued progress in the commercialization of GRAFAPEX, a resilient portfolio of established products, and a strong financial foundation, we believe Medexus is well-positioned to execute on our growth strategy and create long-term value. Appreciate your continued interest and support, and thank you for joining us today.

Operator

Thank you, everyone. This concludes today's event. You may disconnect at this time, and have a wonderful day. Thank you for your participation.